Stockreport

GSK's RSV vaccine, Arexvy, accepted for review by Health Canada for prevention of RSV disease in adults aged 50-59 at increased risk [Yahoo! Finance]

Agenus Inc.  (AGEN) 
Last agenus inc. earnings: 3/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: agenusbio.com/investors
PDF Adults aged 50 and above with underlying medical conditions are at increased risk for RSV disease GSK is the first company to seek regulatory approval to extend RSV v [Read more]